Through a variety of intracellular pathways, blocking the EGF–EGFR connection that results in the loss of a signalling network is essential for inhibiting apoptosis, tumor growth, cellular differentiation and transformation, cell migration and invasion.68 In the last two decades, more than 10 clinical trials were conducted on the use of CIMAvax-EGF after registration. This evidence concerns the gene EGF and neoplasm.